Thomas E. Jenkins
Fondateur chez Elysium Therapeutics, Inc.
Profil
Thomas E.
Jenkins is the founder of Elysium Therapeutics, Inc. which is founded in 2013, where he holds the title of Chief Scientific Officer.
He also held the position of Chief Scientific Officer & Vice President-Research at Signature Therapeutics, Inc. In terms of education, Jenkins holds a doctorate from Stanford University and an undergraduate degree from the University of Akron.
Postes actifs de Thomas E. Jenkins
| Sociétés | Poste | Début |
|---|---|---|
Elysium Therapeutics, Inc.
 Elysium Therapeutics, Inc. BiotechnologyHealth Technology Elysium Therapeutics, Inc. develops pain relievers. The company was founded by Alex Gregory Sturmer and Thomas E. Jenkins in 2013 and is headquartered in Akron, OH. | Fondateur | 01/01/2013 |
Anciens postes connus de Thomas E. Jenkins
| Sociétés | Poste | Fin |
|---|---|---|
Signature Therapeutics, Inc.
 Signature Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Signature Therapeutics, Inc. develops and manufactures pharmaceutical products. It focuses on developing medications for use in pain management and ADHD. Its proprietary BIO-MD platform is designed to deter prescription drug abuse by virtue of strong chemical bonds within the prodrug and also offers solution to the ongoing epidemic of prescription opioid drug abuse. The company was founded by Steven L. Shafer in 2004 and is headquartered in Palo Alto, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Thomas E. Jenkins
| Stanford University | Doctorate Degree |
| University of Akron | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Signature Therapeutics, Inc.
Signature Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Signature Therapeutics, Inc. develops and manufactures pharmaceutical products. It focuses on developing medications for use in pain management and ADHD. Its proprietary BIO-MD platform is designed to deter prescription drug abuse by virtue of strong chemical bonds within the prodrug and also offers solution to the ongoing epidemic of prescription opioid drug abuse. The company was founded by Steven L. Shafer in 2004 and is headquartered in Palo Alto, CA. | Health Technology |
Elysium Therapeutics, Inc.
Elysium Therapeutics, Inc. BiotechnologyHealth Technology Elysium Therapeutics, Inc. develops pain relievers. The company was founded by Alex Gregory Sturmer and Thomas E. Jenkins in 2013 and is headquartered in Akron, OH. | Health Technology |
